Quality of Life Measures to Become Commonplace in Cancer Clinical Trials
A nationwide clinical trial shows improved health-related quality of life (QoL) for young Hodgkin lymphoma patients treated with an immuno-oncologic agent, with fewer negative effects than standard treatment. The study, using brief, paper-based QoL questionnaires, demonstrated high participation and is part of a broader effort to incorporate patient-reported outcomes into cancer treatment and drug approval processes.
Reference News
A nationwide clinical trial shows improved health-related quality of life (QoL) for young Hodgkin lymphoma patients treated with an immuno-oncologic agent, with fewer negative effects than standard treatment. The study, using brief, paper-based QoL questionnaires, demonstrated high participation and is part of a broader effort to incorporate patient-reported outcomes into cancer treatment and drug approval processes.